Fig. 1From: Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancersMetastasis-free survival (MFS) and overall survival (OS) in 323 different subtypes of TNBC (198 of no special type, 43 apocrine, 36 medullary, 13 metaplastic, and 33 rare TNBCs) analyzed in log-rank testsBack to article page